Menu
At Garritz International, our venture into the MedTech sector showcases our unwavering commitment to marrying scientific marketing with cutting-edge data analytics. Our collaboration began in 2017 with an inspiring meeting with Professor Dr. Med. Thomas J. Vogl at Uniklinik Frankfurt, a luminary in radiological science, who presented a visionary proposal for a machine learning-driven CT diagnostic tool specifically for lung carcinoma, titled “Automatisierte Machine-Learning-CT-Diagnostik bei Patienten mit Lungenkarzinomen: Software zur Schnittbildauswertung und Integration klinischer anamnestischer Parameter (ML-CT).”
This project was not merely a technological endeavor but a beacon of hope for advancing medical diagnostics. Inspired, Garritz embraced the challenge to transform this concept into a tangible solution. By September 2018, our innovative blueprint garnered the support of the Hessen government, securing the Löwe 3 project grant, which propelled our research into action.
However, our journey encountered unforeseen hurdles as the COVID-19 pandemic unfolded, stretching global healthcare resources thin and shifting priorities. Despite these challenges, our team’s resilience shone through. We adapted our operational strategies, ensuring continuity in our innovation trajectory, underscored by a profound commitment to health advancements.
Our model underwent rigorous refinements throughout the development phase, learning intricately from manually segmented studies. We employed advanced Python-based libraries for recognition
and radiomic analytics, enhancing the tool’s diagnostic precision. This meticulous process was pivotal in ensuring that the tool met and exceeded the high standards required for medical applications,
providing radiologists with reliable, actionable insights.
In July 2023, this journey culminated in the delivery of the diagnostic tool to Professor Vogl’s department—a milestone that marked not just the successful completion of the project but also a significant leap forward in radiological diagnostics. This tool, now in the hands of medical professionals, offers unprecedented accuracy in diagnosing lung carcinomas, significantly enhancing the ability to treat and understand this grave disease.
As we continue to push the boundaries of MedTech, our journey from a conceptual meeting to delivering a state-of-the-art diagnostic tool stands as a testament to our dedication to transforming healthcare through innovation. Looking forward, we are excited about the opportunities to contribute further to medical science, aiming to significantly enhance patient outcomes across the globe.
Use our contact form to find out more about
AMPEL and how our AI-driven diagnostics are
transforming patient care with clinical precision.